0001415889-23-014345.txt : 20231017
0001415889-23-014345.hdr.sgml : 20231017
20231017164352
ACCESSION NUMBER: 0001415889-23-014345
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231016
FILED AS OF DATE: 20231017
DATE AS OF CHANGE: 20231017
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garland J. Scott
CENTRAL INDEX KEY: 0001533228
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 231330034
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 780 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
4
1
form4-10172023_081046.xml
X0508
4
2023-10-16
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001533228
Garland J. Scott
C/O OLEMA PHARMACEUTICALS, INC.
780 BRANNAN ST
SAN FRANCISCO
CA
94103
true
false
false
false
0
Stock Option (Right to Buy)
10.54
2023-10-16
4
A
0
21520
0
A
2033-10-15
Common Stock
21520
21520
D
Stock Option (Right to Buy)
10.54
2023-10-16
4
A
0
14347
0
A
2033-10-15
Common Stock
14347
14347
D
The shares subject to the option vest in a series of 36 successive equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
The shares subject to the option vest in equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares will vest in full on the earlier of June 16, 2024 and the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
/s/ Shane Kovacs, Attorney-in-Fact
2023-10-17